Literature DB >> 16181458

The objective severity assessment of atopic dermatitis (OSAAD) score: validity, reliability and sensitivity in adult patients with atopic dermatitis.

I Angelova-Fischer1, A Bauer, U C Hipler, I Petrov, J Kazandjieva, T Bruckner, T Diepgen, N Tsankov, M Williams, T W Fischer, P Elsner, J W Fluhr.   

Abstract

BACKGROUND: The Objective Severity Assessment of Atopic Dermatitis (OSAAD) score is a recently developed scale for evaluation of severity of atopic dermatitis, constructed from the assessment of epidermal barrier function, and properties using noninvasive bioengineering methods and computer-assisted estimates of disease extent. The method has been validated for use in infants and children with atopic dermatitis and compared with a referent scoring system.
OBJECTIVES: The aim of the present study was to test the validity, reliability and sensitivity of the OSAAD score as an objective tool for the assessment of the severity of atopic dermatitis in adult patients.
METHODS: Thirty-two adult patients with atopic dermatitis were included in the study. To assess the validity of the OSAAD score we tested it against the Severity Scoring of Atopic Dermatitis (SCORAD) index of the European Task Force on Atopic Dermatitis as a referent clinical severity scale, and the serum levels of interleukin (IL)-16 as a laboratory variable for monitoring the activity of atopic dermatitis. Responsiveness to change was assessed in a longitudinal study comparing OSAAD, SCORAD and serum levels of IL-16 before and after treatment. To test the reliability of the OSAAD score we studied the interobserver variability of the score recorded by three independent board-certified dermatologists in 16 patients and compared it with SCORAD.
RESULTS: We report a significant correlation between the OSAAD and the SCORAD index as an acknowledged referent severity scale. The OSAAD score correlated significantly with the serum levels of IL-16 in the acute stage of atopic dermatitis. In a longitudinal study, the OSAAD score decreased significantly, parallel with improvement of the skin findings and a significant decrease in the SCORAD score and IL-16 serum levels. We report improved interobserver variability for the OSAAD score compared with SCORAD.
CONCLUSIONS: This is the first study validating the OSAAD score as a sensitive and reliable tool for the assessment of the severity of atopic dermatitis in adult patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16181458     DOI: 10.1111/j.1365-2133.2005.06697.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  13 in total

1.  Effect of maternal ω3 fatty acid supplementation on infant allergy.

Authors:  Christina E Ciaccio; Manika Girdhar
Journal:  Ann Allergy Asthma Immunol       Date:  2014-03       Impact factor: 6.347

2.  Assessment of a correlation between Canine Atopic Dermatitis Extent and Severity Index (CADESI-03) and selected biophysical skin measures (skin hydration, pH, and erythema intensity) in dogs with naturally occurring atopic dermatitis.

Authors:  Marcin Zając; Marcin P Szczepanik; Piotr M Wilkołek; Łukasz R Adamek; Zbigniew J H Pomorski; Wiesław Sitkowski; Marcin Gołyński
Journal:  Can J Vet Res       Date:  2015-04       Impact factor: 1.310

Review 3.  Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.

Authors:  Lawrence F Eichenfield; Wynnis L Tom; Sarah L Chamlin; Steven R Feldman; Jon M Hanifin; Eric L Simpson; Timothy G Berger; James N Bergman; David E Cohen; Kevin D Cooper; Kelly M Cordoro; Dawn M Davis; Alfons Krol; David J Margolis; Amy S Paller; Kathryn Schwarzenberger; Robert A Silverman; Hywel C Williams; Craig A Elmets; Julie Block; Christopher G Harrod; Wendy Smith Begolka; Robert Sidbury
Journal:  J Am Acad Dermatol       Date:  2013-11-27       Impact factor: 11.527

4.  On the effects of topical synthetic pseudoceramides: comparison of possible keratinocyte toxicities provoked by the pseudoceramides, PC104 and BIO391, and natural ceramides.

Authors:  Yoshikazu Uchida; Walter M Holleran; Peter M Elias
Journal:  J Dermatol Sci       Date:  2008-04-08       Impact factor: 4.563

Review 5.  Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010.

Authors:  Balvinder Rehal; April W Armstrong; April Armstrong
Journal:  PLoS One       Date:  2011-04-13       Impact factor: 3.240

6.  Efficacy of combined peroxisome proliferator-activated receptor-α ligand and glucocorticoid therapy in a murine model of atopic dermatitis.

Authors:  Yutaka Hatano; Peter M Elias; Debra Crumrine; Kenneth R Feingold; Kazumoto Katagiri; Sakuhei Fujiwara
Journal:  J Invest Dermatol       Date:  2011-06-02       Impact factor: 8.551

7.  Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells.

Authors:  Jeong Chan Ra; Sung Keun Kang; Il Seob Shin; Hyeong Geun Park; Sang Aun Joo; Jeong Geun Kim; Byeong-Cheol Kang; Yong Soon Lee; Ken Nakama; Min Piao; Bertram Sohl; Andras Kurtz
Journal:  J Transl Med       Date:  2011-10-21       Impact factor: 5.531

8.  Therapeutic effects and immunomodulation of suanbo mineral water therapy in a murine model of atopic dermatitis.

Authors:  Yoon Jung Choi; Hye Jin Lee; Do Hyun Lee; So Youn Woo; Kyung Ho Lee; Seong Taek Yun; Jong Moon Kim; Hong Jig Kim; Jin Wou Kim
Journal:  Ann Dermatol       Date:  2013-11-30       Impact factor: 1.444

9.  7,8,4'-Trihydroxyisoflavone attenuates DNCB-induced atopic dermatitis-like symptoms in NC/Nga mice.

Authors:  Heejung Kim; Jong Rhan Kim; Heerim Kang; Jinhwan Choi; Hee Yang; Pomjoo Lee; Jiyoung Kim; Ki Won Lee
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

10.  Differences in Psychometric Properties of Clinician- and Patient-Reported Outcome Measures for Atopic Dermatitis by Race and Skin Tone: A Systematic Review.

Authors:  Trisha Kaundinya; Uros Rakita; Armaan Guraya; Donna Maria Abboud; Emily Croce; Jacob P Thyssen; Andrew Alexis; Jonathan I Silverberg
Journal:  J Invest Dermatol       Date:  2021-08-02       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.